M16-01: Role of biology and genetics in lung cancer in women  by Unger, Michael
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS192
6. Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, Gazdar AF, Wis-
tuba, II. EGFR tyrosine kinase domain mutations are detected in histologically normal 
respiratory epithelium in lung cancer patients. Cancer research 2005;65(17):7568-72.
M15-03 Genetics and Epigenetics in Lung Carcinogenesis, Thur, Sept 6, 10:30 - 12:00
Molecular changes in invasion, tumor progression and metastasis
Wistuba, Ignacio 
MD Anderson Cancer Center, Houston, TX, USA
Despite major improvements in patient management, the prognosis for 
patients with lung cancer remains dismal. From biological, histo-
pathologic and clinical perspectives, lung cancer is a highly complex 
neoplasm probably having multiple preneoplastic and tumor progres-
sion pathways. Non-small cell lung cancer (NSCLC) represents nearly 
80% of lung tumors, and the major histological types are squamous 
cell carcinoma and adenocarcinoma. Both tumor types are believed to 
arise after a sequential progression of pre-malignant lesions, including 
bronchial squamous metaplasia and dysplasias for squamous cell carci-
noma, and peripheral atypical adenomatous hyperplasia for a subset of 
adenocarcinomas. 
As our knowledge of the molecular basis of lung cancer pathogenesis, 
progression and metastasis has increased, new molecular abnormalities 
and novel targets for therapeutic interventions have been identiﬁed. 
After decades of separate but not equal investigation efforts, prevention 
and therapy are beginning to converge at the level of early-phase clini-
cal testing. This highly beneﬁcial convergence has encouraged the in-
vestigation of known and novel molecular abnormalities at a) progres-
sion and invasion of lung preneoplastic lesions, b) tumor progression 
phenomenon (locally early vs. advanced tumors) and, c) metastasis pro-
cess. Although multiple lung cancer-related molecular pathways have 
been recognized to be involved in those lung cancer stages, there is no 
extensive information of their involvement in the multistep develop-
ment and progression of lung tumor. Using a comprehensive molecular 
pathology approach, we are currently investigating the role of several 
key molecularly abnormal pathways in the early pathogenesis, tumor 
progression and metastasis of lung cancer, including tyrosine kinase 
receptors, epithelial mesenchymal transition (EMT), angiogenesis and 
stem cells markers. 
Our recent studies indicate that multiple molecular pathways are dif-
ferentially disregulated in the early pathogenesis of the major types of 
lung cancer, including, among others, inﬂammation-related changes, 
inactivation of multiple tumor suppressor genes, and the activation 
of multiple tyrosine kinases, particularly receptor tyrosine kinases. 
Recently, using a molecular mapping strategy, we have characterized 
the EGFR molecular abnormalities in the early pathogenesis of lung 
adenocarcinomas, and demonstrated that the activation of the nuclear 
factor kappa B (NF-κB) and the insulin-like growth (IGF) factor axis 
are frequent phenomena in the early progression of squamous cell 
carcinoma of the lung. In addition, our unpublished data suggest that 
the EMT phenomenon also plays an important role in lung cancer early 
pathogenesis. 
The molecular events involved in the local progression of lung cancers 
have not been well studied. These studies require the application of 
molecular pathology-based mapping strategies to study the molecularly 
abnormal clonal expansion of tumor cells. Our recent studies on EGFR 
molecular changes (mutation, copy number and protein expression) and 
in the immunohistochemical expression of multiple markers suggest 
that molecular heterogeneity is present in lung cancer specimens, and 
they need to be further studied to understand the local progression of 
lung tumors. 
Although the mechanisms involved in lung cancer metastasis are not 
well understood, it is believed that biologically heterogeneous tumors 
contain subpopulations of cells with different invasive and metastatic 
properties. To produce metastasis, tumor cells must complete a series of 
selective and sequential steps. Our recent ﬁndings indicate that primary 
tumor and brain metastasis share multiple molecular abnormalities; 
however, they differ in the pattern and characteristics of some mo-
lecular changes, including HER family receptors and ligands expres-
sion. On the other hand, recent studies indicate that to produce brain 
metastasis, tumor cells must reach the vasculature of the brain, attach to 
the microvessel endothelial cells, extravasate into the parenchyma, pro-
liferate, and induce angiogenesis. Although there are currently major 
efforts in the identiﬁcation of lung cancer stem cells markers, there is 
no data available on the role of these subpopulation of malignant cells 
in the development of lung cancer metastasis.
During the last decade, encouraged by the development of methodolo-
gies for isolation of cells from small histologic lesions, such as laser 
microdissection, combined with techniques to perform genomic studies 
from minute amount of DNA, RNA and protein, several groups have 
made substantial progress on unveiling the molecular and genetic 
abnormalities of lung cancer precursor lesions, tumor progression and 
metastasis, including those evolving to centrally located squamous cell 
carcinoma and peripheral adenocarcinoma. The recent development of 
a panel of human normal bronchial epithelial cells immortalized, which 
can be modiﬁed with a combination of oncogenes activation (EGFR, 
KRAS) and tumor suppressor (TP53) gene knockdowns for in vitro 
discovery work, coupled with the development of more relevant lung 
cancer animal models and new high-throughput genomic and proteomic 
proﬁling techniques that can be applied to small amount of microdis-
sected tissues may stimulate the scientiﬁc community to perform inno-
vative investigations in the ﬁelds of molecular and pathology research.
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Within a period of less than one hundred years, lung cancer has be-
come the leading global cause of death among men and subsequently 
women. The new millennium was ushered by frightening statistics of 
rapidly evolving incidents and mortality from this disease. The role of 
increased as well as changing pattern of tobacco use was shown to be a 
cause of many diseases, and in particular, lung cancer. 
The accelerated rate of incidents of lung cancer and the decreasing ratio 
between men and women raised the issue of increased susceptibility 
of women to this disease. Many case controlled studies suggested that 
indeed, women might be more susceptible to develop lung neoplastic 
process. On the other hand, other cohort studies tend to refute this 
notion. In view of signiﬁcant coexistence and association of chronic 
obstructive pulmonary disease and lung cancer, questions are being 
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raised as to whether there is common genetic susceptibility connection 
between the two diseases, considering the risk associated with tobacco 
smoking or independent of it.
Similarly, there is a growing amount of data pointing to differences 
between the sexes, regarding the pattern of disease, its morbidity, the 
response to interventions or therapy, and mortality from primary lung 
cancer. The task of present and future research is to elucidate answers 
to these questions on the basis of different biology and genetics. 
A certain degree of confusion was introduced through indiscriminate 
and sometimes inappropriately interchanged uses of the terms sex and 
gender. Both gender and sex linked factors relate to risk of developing 
lung cancer and therapeutic implications.
In gender related risk factors, smoking plays a major role, probably in 
girls and boys as well as in adult women and men. In both youth and 
adulthood, the type of tobacco used as much as the way of smoking 
play a role. There are however other risk factors, including environ-
mental tobacco smoke, cooking fuels and fumes, employment, environ-
mental pollution, and nutrition. Each of these might interact also with 
sex-linked factors. 
The sex linked factors will generate biological differences on one hand, 
and genetic ones, on the other. 
The biological differences are rooted mostly in reproductive hormones. 
Several factors have to be considered in risk assessment like the onset 
of menarch, length of menstrual cycle, and use of hormone replacement 
therapy. Estrogens are probably playing a role in lung tumorigenesis 
at many levels. They may act as ligands to estrogen receptors activat-
ing cellular proliferation pathways. They may also undergo metabolic 
activation to reactive intermediates resulting in formation of DNA 
adducts or cause oxidative damage. Estrogen receptor beta (ER-beta) 
is the primary receptor expressed in lung tumors and studies suggest its 
activation inﬂuences lung tumor cell proliferation. On the other hand 
there no sex difference in expression of this receptor which suggests 
that this might not be dependent on the level of endogenous estrogens. 
Interaction between the ER-beta and Epidermal Growth Factor Recep-
tor (EGFR) might have therapeutic implications. Each and every one 
of these, however, is also dependent on the age of the subject as well 
as smoking status and interaction of the inhaled substances on the hor-
monal metabolism. These complicated data then, should be taken into 
account when planning recruitment and sample size of a given study. 
Sex-linked factors also inﬂuence the genetic differences between men 
and women. Women are more likely than men to carry various genetic 
mutations which, similar to biological differences, will be reﬂected 
in risk assessment, increased susceptibility to develop lung cancer on 
one hand, and response to therapy on the other. Here, once more, the 
increased risk for women can be inﬂuenced by tobacco smoking effects 
through nicotine and metabolism of other carcinogens and their interac-
tion with hormonal effects.
Two classes of enzymes are crucial in the metabolism of tobacco-relat-
ed carcinogens-the phase I and phase II enzymes. The phase I enzymes 
responsible for activation of carcinogens to reactive intermediates 
are counterbalanced by phase II enzymes having a salutary effect of 
converting these reactive intermediates to inactive conjugates which 
then can be eliminated. The toxic intermediates bind to the DNA form-
ing detectable DNA adducts. Increased levels of DNA adducts were 
found in women with lung cancer then in men. This increase in adducts 
was correlated with expression of cytochrome P450s (CYP1A1) and 
glutathione-S- transferases (GST) polymorphism associated with 
metabolic activity of detoxiﬁcation (phase II) enzymes and also induc-
tion of p53 mutations ( higher G-to-T transversion). The p53 mutations 
then contribute to perpetuation of DNA damage. Among lung cancer in 
never smokers a different pattern of mutations of p53 was found in men 
and women.
There appears to be also a pivotal role of DNA adducts on K ras muta-
tion which are more prevalent ( after controlling for tobacco effects) in 
women and associated predominantly with adenocarcinomas. 
Series of various genetic mutations are considered as putative factors 
in increased carcinogenesis or development of speciﬁc type of lung 
cancer. Other genetic factors are potentially responsible for variability 
in DNA repair mechanism and decreased recovery from DNA damage 
as well as sensitivity or resistance to chemotherapy or other responses 
to therapeutic modalities. 
The removal of damaged DNA segments or repair of mismatched 
nucleotides is controlled by a complex family of proteins. Recent stud-
ies suggest that the capacity of repair of the DNA is lower in younger 
patients with family history of lung cancer and in women. Paradoxical-
ly also this reduced repair might be responsible for development of less 
resistance to platinum based chemotherapy since the effects of platinum 
is through formation of DNA adducts leading to arrest of proliferation 
cycle and apoptosis. Studies demonstrating reduction of DNA repair 
suggest better outcome and less development of resistance to therapy.
EGFR mutations (primarily in exons 18, 19, 21) are associated with 
increased response rate to tyrosine kinase inhibitors (TKIs). The rate 
of mutations decreases with smoking they are apparently expressed 
more in women of East Asian origin where there are also reports of 
increased therapeutic responses. At the same time the toxicity from 
treatment with EGFR inhibitors (neurosensory, nausea, vomiting, alo-
pecia and neuro-psychiatric) was recorded to be higher in women then 
men. Bronchoalveolar carcinoma in non smokers is diagnosed more 
frequently in women then men and women also show better response to 
therapy with TKI inhibitors.
The association between male-female ratio and survival from lung can-
cer has been better documented then the association of the ratio with 
incidence of the disease. Overall women’s stage-for-stage improved 
survival applies to all histological types of lung cancer. Recent study 
documenting improved survival in women 65 and older with stage I 
and II lung cancer even when untreated suggests that female lung can-
cer has different natural history and potentially different tumor biology. 
Further extensive studies are required to elucidate in women with and 
without exposure to tobacco the biological and genetic role in rela-
tive risk for developing lung cancer, natural history of the primary and 
metastatic malignancy and potential therapeutic advantages. 
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Approximately 10% to 15% of lung cancer patients are never-smokers. 
Lung cancer in never-smokers (LCINS) is more frequently diagnosed 
in women than in men. Toh et al evaluated 883 NSCLC patients diag-
nosed in Singapore between 1999 and 2002. Of 286 never-smokers, 
68.5% were women compared with just 12% women among current 
and former-smokers. However, the fact that there is a signiﬁcantly 
greater proportion of never-smoker women than there are men may 
well contribute to the higher incidence of LCINS observed among 
women. SCLC and squamous cell carcinoma are extremely uncommon 
